Floatz logo

BIFEPRUNOX

Bipolar Disorder

Solvay PharmaceuticalsSmall moleculePhase 3Dormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
73/ 100

Competitive context

67 Active assets in the Bipolar Disorder cohort.

Asset / SponsorPhaseRating
Asenapine
Dr. Stavroula Rakitzi
Phase 4BBB
LITHIUM, ELEMENTAL
University of Aarhus
Phase 4BBB
CITALOPRAM
University of Texas Southwestern Medical Center
Phase 4BBB
Seroquel®
First Affiliated Hospital of Zhejiang University
Phase 4BBB
Paroxetine
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

BIFEPRUNOX is also rated in:

schizophreniaDormant
B
Indicative ·
61 / 100
View asset →
schizoaffective disorderDormant
B
Indicative ·
60 / 100
View asset →
Alzheimer diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →